Rhumbline Advisers Tg Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 382,609 shares of TGTX stock, worth $11.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
382,609
Previous 215,055 77.91%
Holding current value
$11.3 Million
Previous $3.83 Million 133.96%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$17.21 - $25.28 $2.88 Million - $4.24 Million
167,554 Added 77.91%
382,609 $8.95 Million
Q2 2024

Aug 01, 2024
BUY
$13.32 - $19.19 $207,552 - $299,018
15,582 Added 7.81%
215,055 $3.83 Million
Q1 2024

May 09, 2024
BUY
$13.02 - $21.3 $78,054 - $127,693
5,995 Added 3.1%
199,473 $3.03 Million
Q4 2023

Feb 08, 2024
BUY
$6.68 - $18.81 $28,536 - $80,356
4,272 Added 2.26%
193,478 $3.3 Million
Q3 2023

Nov 09, 2023
SELL
$8.36 - $26.5 $2,123 - $6,731
-254 Reduced 0.13%
189,206 $1.58 Million
Q2 2023

Aug 08, 2023
BUY
$15.48 - $35.0 $155,419 - $351,400
10,040 Added 5.6%
189,460 $4.71 Million
Q1 2023

May 11, 2023
BUY
$10.23 - $19.34 $83,036 - $156,982
8,117 Added 4.74%
179,420 $2.7 Million
Q4 2022

Feb 14, 2023
BUY
$5.01 - $11.83 $43,947 - $103,772
8,772 Added 5.4%
171,303 $2.03 Million
Q3 2022

Nov 10, 2022
BUY
$4.57 - $8.4 $50,471 - $92,769
11,044 Added 7.29%
162,531 $962,000
Q2 2022

Aug 11, 2022
BUY
$3.74 - $10.66 $72,739 - $207,326
19,449 Added 14.73%
151,487 $644,000
Q1 2022

May 12, 2022
BUY
$7.81 - $20.45 $4,318 - $11,308
553 Added 0.42%
132,038 $1.26 Million
Q4 2021

Feb 10, 2022
SELL
$15.2 - $35.51 $22,192 - $51,844
-1,460 Reduced 1.1%
131,485 $2.5 Million
Q3 2021

Nov 12, 2021
BUY
$21.78 - $40.45 $48,395 - $89,879
2,222 Added 1.7%
132,945 $4.42 Million
Q2 2021

Aug 05, 2021
SELL
$32.5 - $48.96 $433,517 - $653,077
-13,339 Reduced 9.26%
130,723 $5.07 Million
Q1 2021

May 06, 2021
SELL
$41.61 - $54.3 $153,083 - $199,769
-3,679 Reduced 2.49%
144,062 $6.94 Million
Q4 2020

Feb 10, 2021
BUY
$25.27 - $54.9 $420,012 - $912,492
16,621 Added 12.68%
147,741 $7.69 Million
Q3 2020

Nov 12, 2020
SELL
$18.49 - $27.24 $318,582 - $469,345
-17,230 Reduced 11.61%
131,120 $3.51 Million
Q2 2020

Aug 13, 2020
BUY
$8.9 - $21.84 $266,172 - $653,168
29,907 Added 25.25%
148,350 $2.89 Million
Q1 2020

May 06, 2020
BUY
$7.14 - $15.99 $120,087 - $268,935
16,819 Added 16.55%
118,443 $1.17 Million
Q4 2019

Feb 05, 2020
BUY
$5.1 - $11.2 $30,319 - $66,584
5,945 Added 6.21%
101,624 $1.13 Million
Q3 2019

Oct 23, 2019
BUY
$5.38 - $8.99 $10,630 - $17,764
1,976 Added 2.11%
95,679 $537,000
Q2 2019

Aug 14, 2019
BUY
$6.27 - $8.65 $100,257 - $138,313
15,990 Added 20.58%
93,703 $811,000
Q1 2019

May 01, 2019
SELL
$4.02 - $8.04 $4,763 - $9,527
-1,185 Reduced 1.5%
77,713 $625,000
Q4 2018

Jan 31, 2019
BUY
$3.44 - $5.76 $92,467 - $154,828
26,880 Added 51.67%
78,898 $323,000
Q3 2018

Nov 07, 2018
SELL
$5.15 - $14.0 $13,230 - $35,966
-2,569 Reduced 4.71%
52,018 $291,000
Q2 2018

Aug 06, 2018
BUY
$12.5 - $15.0 $105,437 - $126,525
8,435 Added 18.28%
54,587 $718,000
Q1 2018

May 02, 2018
BUY
$8.7 - $16.8 $12,875 - $24,864
1,480 Added 3.31%
46,152 $655,000
Q4 2017

Feb 09, 2018
SELL
$7.35 - $12.3 $63,357 - $106,026
-8,620 Reduced 16.18%
44,672 $366,000
Q3 2017

Nov 06, 2017
BUY
$10.0 - $12.7 $532,920 - $676,808
53,292
53,292 $632,000

Others Institutions Holding TGTX

# of Institutions
338
Shares Held
88.3M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email